Program
tezacaftor
Also written as “ELX/TEZ/IVA”, “TEZ/IVA” and “TEZ”.
Its studies are mostly in Cystic Fibrosis, led by Vertex Pharmaceuticals.
Furthest: phase 3, since Jan 12, 201539 company-led studies, 4 open or runningNext primary completion: Apr 6, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vertex Pharmaceuticals | 394 open or running | phase 3since Jan 12, 2015 | Feb 1, 2012 | Apr 6, 2027phase 3 · NCT05331183 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 26 studies since Feb 1, 2012.
- Aug 28, 2020Phase 3 study in Cystic FibrosisNCT04537793 · 83 enrolled · United States, Australia, Canada and more
- Sep 3, 2020Phase 3 study in Cystic FibrosisNCT04545515 · 120 enrolled · Australia, Canada, Denmark and more
- Oct 21, 2020Phase 3 study in Cystic FibrosisNCT04599465 · 69 enrolled · Australia, Belgium, Czechia and more
- Jul 9, 2021Phase 3 study in Cystic FibrosisNCT04969224 · 82 enrolled · Australia, Belgium, Canada and more
- Oct 27, 2021Phase 3 study in Cystic FibrosisNCT05111145 · 86 enrolled · Australia, Belgium, Canada and more
- Nov 29, 2021Phase 3 study in Cystic FibrosisNCT05153317 · 71 enrolled · United States, Australia, Canada and more
- Mar 1, 2022Phase 3 study in Cystic FibrosisNCT05274269 · 307 enrolled · Austria, Belgium, Canada and more
- Apr 8, 2022Phase 3 study in Cystic FibrosisNCT05331183 · 297 enrolled · Austria, Belgium, Canada and more
- May 19, 2023Phase 3 study in Cystic FibrosisNCT05882357 · 67 enrolled · Australia, Canada, Denmark and more
- Nov 23, 2023Phase 1 study in Cystic FibrosisNCT06154447 · 165 enrolled · United States
- Jun 10, 2024Phase 3 study in Cystic FibrosisNCT06460506 · 50 enrolled · Australia, Canada, Denmark and more
- Dec 4, 2025Phase 1 study in Cystic FibrosisNCT07283770 · 152 planned · United States
- Feb 20, 2026Phase 1 study in Cystic FibrosisNCT07437105 · 160 planned · United States
- Oct 19, 2026Primary completion moved from 2026-11-19 to 2027-07-12Date moved laterphase 1 · +8 months · NCT07283770
Ahead
- Apr 6, 2027Primary completion: phase 3 study in Cystic FibrosisNCT05331183
- Jun 26, 2027Primary completion: phase 1 study in Cystic FibrosisNCT07437105
- Jul 12, 2027Primary completion: phase 1 study in Cystic FibrosisNCT07283770
- Sep 30, 2027Primary completion: phase 3 study in Cystic FibrosisNCT06460506
TargetBeta
CFTR →read by rule
“Cystic fibrosis transmembrane conductance regulator positive modulator”ChEMBL 37, by rule
Other programs on CFTR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivacaftorrule | Vertex Pharmaceuticals | phase 4 | 78 |
| lumacaftorrule | Vertex Pharmaceuticals | phase 4 | 23 |
Studies
All 39 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07437105Cystic Fibrosis · United States | 1 | Recruiting | Jun 26, 2027 | 160 |
| NCT07283770Cystic Fibrosis · United States | 1 | Recruiting | Jul 12, 2027 | 152 |
| NCT06460506Cystic Fibrosis · Australia, Canada, Denmark and more | 3 | Active, not recruiting | Sep 30, 2027 | 50 |
| NCT06154447Cystic Fibrosis · United States | 1 | Completed | Jul 10, 2026 | 165 |
| NCT05882357Cystic Fibrosis · Australia, Canada, Denmark and more | 3 | Completed | Sep 4, 2025 | 67 |
| NCT05331183Cystic Fibrosis · Austria, Belgium, Canada and more | 3 | Active, not recruiting | Apr 6, 2027 | 297 |
| NCT05274269Cystic Fibrosis · Austria, Belgium, Canada and more | 3 | Completed | Jul 5, 2023 | 307 |
| NCT05153317Cystic Fibrosis · United States, Australia, Canada and more | 3 | Completed | Jan 29, 2026 | 71 |
| NCT05111145Cystic Fibrosis · Australia, Belgium, Canada and more | 3 | Completed | Dec 20, 2022 | 86 |
| NCT04969224Cystic Fibrosis · Australia, Belgium, Canada and more | 3 | Completed | Jul 26, 2022 | 82 |
| NCT04599465Cystic Fibrosis · Australia, Belgium, Czechia and more | 3 | Completed | Jul 14, 2022 | 69 |
| NCT04545515Cystic Fibrosis · Australia, Canada, Denmark and more | 3 | Completed | Mar 24, 2023 | 120 |
| NCT04537793Cystic Fibrosis · United States, Australia, Canada and more | 3 | Completed | Jun 3, 2022 | 83 |
| NCT04362761Cystic Fibrosis · Australia, Belgium, Germany and more | 3 | Completed | Dec 21, 2022 | 172 |
| NCT04353817Cystic Fibrosis · Australia, Canada, Denmark and more | 3 | Completed | May 17, 2021 | 121 |
| NCT04183790Cystic Fibrosis · United States, Australia, Canada and more | 3 | Completed | Feb 24, 2024 | 64 |
| NCT04058366Cystic Fibrosis · United States, Australia, Belgium and more | 3 | Completed | Dec 16, 2022 | 251 |
| NCT03768089Cystic Fibrosis · Netherlands, United Kingdom | 2 | Completed | May 3, 2019 | 115 |
| NCT03691779Cystic Fibrosis · United States, Australia, Canada and more | 3 | Completed | Aug 7, 2020 | 71 |
| NCT03559062Cystic Fibrosis · Australia, Belgium, Denmark and more | 3 | Completed | Dec 21, 2018 | 67 |
| NCT03537651Cystic Fibrosis · United States, Australia, Belgium and more | 3 | Completed | Oct 28, 2020 | 130 |
| NCT03525574Cystic Fibrosis · United States, Australia, Austria and more | 3 | Completed | Jan 9, 2023 | 507 |
| NCT03486236Cystic Fibrosis · United Kingdom | 1 | Completed | Sep 14, 2016 | 16 |
| NCT03227471Cystic Fibrosis · United States, Australia, Belgium and more | 2 | Completed | Mar 27, 2018 | 225 |
| NCT03224351Cystic Fibrosis · United States, Ireland, Israel and more | 2 | Completed | Feb 28, 2018 | 124 |
| NCT03150719Cystic Fibrosis · United States, France, Germany | 3 | Completed | Aug 9, 2018 | 98 |
| NCT02951195Cystic Fibrosis · United States | 2 | Completed | Jan 2018 | 80 |
| NCT02951182Cystic Fibrosis · United States, Australia, Austria and more | 2 | Completed | Aug 2017 | 74 |
| NCT02953314Cystic Fibrosis · United States, Canada | 3 | Completed | Sep 2018 | 83 |
| NCT02730208Cystic Fibrosis · Australia | 2 | Completed | Jul 2018 | 41 |
| NCT02565914Cystic Fibrosis · United States, Australia, Austria and more | 3 | Completed | May 2019 | 1,131 |
| NCT02516410Cystic Fibrosis · United States, Australia, Austria and more | 3 | Completed | Jun 7, 2016 | 168 |
| NCT02508207Cystic Fibrosis · United States | 2 | Completed | Jun 2017 | 34 |
| NCT02412111Cystic Fibrosis · United States, Australia, Austria and more | 3 | Completed | Sep 2017 | 156 |
| NCT02392234Cystic Fibrosis · United States, Australia, Belgium and more | 3 | Completed | Feb 2017 | 248 |
| NCT02347657Cystic Fibrosis · United States, Canada, Denmark and more | 3 | Completed | Jan 20, 2017 | 510 |
| NCT02070744Cystic Fibrosis · United States | 2 | Completed | May 27, 2016 | 40 |
| NCT02015507Cystic Fibrosis | 1 | Completed | Feb 2014 | 34 |
| NCT01531673Cystic Fibrosis · United States, Canada, Germany and more | 2 | Completed | Mar 2014 | 194 |
How it is read
Names in the registry
- “ELX/TEZ/IVA”, 16 entries
- “TEZ/IVA”, 8 entries
- “TEZ”, 4 entries
- “Tezacaftor/Ivacaftor”, 4 entries
- “VX-661”, 3 entries
Codes read as this program: VX661.
Conditions, from the studies’ own filings
- Cystic Fibrosis, 39 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.